Results 21 to 30 of about 542,975 (311)

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma

Urological Science, 2019
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the paradigm of anticancer therapy in many cancer types, including advanced urothelial carcinoma (UC).
Jhe-Cyuan Guo, Yu-Chieh Tsai, Yeong-Shiau Pu   +2 more
doaj   +1 more source

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Polish Journal of Pathology, 2021
Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin, Emine Bagir, Merve Inceman, Mutlu Deger, Seyda Erdogan   +4 more
doaj   +1 more source

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +3 more sources

Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer

Zhongliu Fangzhi Yanjiu, 2023
Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS.
DENG Changgang, ZHANG Wei, SUN Yanyu, LI Qisui, HUANG Wei, YUAN Jing   +5 more
doaj   +1 more source

The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor [PDF]

Cureus, 2018
Tumor therapy has evolved greatly since the discovery of immunotherapies. New therapies permit targeted approach with less side effects. Immunotherapies target specific components recognized on tumor cells, such as Programmed death-1 (PD-1). Overexpression of PD-1 markers in solid gastrointestinal tumors is a consequence of deficiency in DNA mismatch ...
Al Attar, Layth, Truong, Phu
openaire   +2 more sources

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2017
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system ...
Zhansheng JIANG, Zhanyu PAN, Xiubao REN
doaj   +1 more source

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: Breast cancer is the most common malignant tumour and the leading cause of cancer-related death in women is breast cancer. The Immunohistochemistry (IHC) method utilised antigens and antibodies to interact to identify cellular or tissue
Shreya Ghosh, Jayant S Makarande, Sunita Vagha, Anil K Agrawal, Sahitya Vodithala   +4 more
doaj   +1 more source

Both the Caspase CSP-1 and a Caspase-Independent Pathway Promote Programmed Cell Death in Parallel to the Canonical Pathway for Apoptosis in Caenorhabditis elegans [PDF]

, 2012
Caspases are cysteine proteases that can drive apoptosis in metazoans and have critical functions in the elimination of cells during development, the maintenance of tissue homeostasis, and responses to cellular damage. Although a growing body of research
A Cauwels, A Degterev, A Gartner, A Raj, AH Wyllie, AM Chinnaiyan, B Conradt, B Pinan-Lucarre, B Schumacher, BT Hyman, D Xue, D Xue, Daniel P. Denning, DJ Dwyer, DJ Hoeppner, DP Denning, DT Harris, E Arama, E Pourkarimi, EC Andersen, EH Cheng, EM Hedgecock, ES Blum, F Chen, F Madeo, F Simmer, H. Robert Horvitz, HC Chang, Hermann Steller, HM Ellis, HT Schwartz, J Yuan, J Yuan, JE Sulston, JE Sulston, JF Kerr, JM Kinchen, JY Yuan, K Xu, M Darland-Ransom, MC Abraham, MC Abraham, MO Hengartner, MO Hengartner, NA Thornberry, PW Reddien, RA Lockshin, RE Ellis, S Brenner, S Harbinder, S Qi, S Seshagiri, S Shaham, S Shaham, S Shaham, SA Susin, T Hirose, TL Gumienny, V Venegas, VA Fadok, Victoria Hatch, X Geng, X Geng, X Wang, X Yang, Z Zhou   +65 more
core   +4 more sources

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1 [PDF]

JAMA Oncology, 2019
Therapies to inhibit programmed cell death 1 and its ligand (anti-PD-1/PD-L1) provide significant survival benefits in many cancers, but the efficacy of these treatments varies considerably across different cancer types. Identifying the underlying variables associated with this cancer type-specific response remains an important open research challenge ...
Joo Sang, Lee, Eytan, Ruppin
openaire   +2 more sources

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia

Human Vaccines & Immunotherapeutics, 2018
The present study is to measure the expression of programmed death (PD)-1 / programmed death ligand-1 (PD-L1) negative costimulatory molecules, soluble format sPD-1 in patients with immune thrombocytopenia (ITP), and to investigate their correlation with
Yingying Wang, Nannan Pang, Xinyou Wang, Ying Liu, Xiujuan Wang, Lei Wang, Mingling Sun, Halida Yasen, Fang Zhao, Wenxia Fan, Xinhong Guo, Jianbing Ding   +11 more
doaj   +1 more source